Allarity Therapeutics to Present at Biomarkers 2024

Core Viewpoint - Allarity Therapeutics is advancing its personalized cancer treatment approach through the Drug Response Predictor (DRP®) platform, which is being showcased at Biomarkers 2024, highlighting its ongoing clinical trial for advanced ovarian cancer patients [1][2][3]. Company Overview - Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing personalized cancer treatments, particularly stenoparib, a dual PARP/Tankyrase inhibitor for advanced ovarian cancer [5]. - The company is headquartered in the U.S. and has a research facility in Denmark, aiming to address significant unmet medical needs in cancer treatment [5]. Drug Response Predictor (DRP®) Platform - The DRP® platform is designed to select patients based on their cancer's expression signature, predicting their likelihood of benefiting from specific drugs [4]. - The platform has shown a statistically significant prediction of clinical outcomes in 37 out of 47 clinical studies reviewed, indicating its effectiveness across various cancer types [4]. Clinical Trials - Allarity is conducting a phase 2 clinical trial (NCT03878849) for stenoparib, utilizing the DRP® to pre-select advanced ovarian cancer patients who are likely to benefit from the treatment [2][5]. - The ongoing trial is being conducted at multiple sites across the U.S. and Europe, emphasizing the company's commitment to rigorous clinical validation [2]. Presentation at Biomarkers 2024 - CEO Thomas Jensen will present at Biomarkers 2024, discussing a gene expression-based biomarker for predicting treatment response, scheduled for February 29, 2024, in London, UK [3]. - Attendees are encouraged to schedule one-on-one meetings with Mr. Jensen to explore business development opportunities [3].